The Daily Beast: These Therapists Want to Help You Trip on Shrooms and Ecstasy

Summary: The Daily Beast explores research into MDMA and psilocybin treatments, highlighting promising study results, progress toward potential FDA approval, and the importance of equitable access for psychedelic therapy.

“Considering the persuasiveness of the last 15 years of clinical research, many medical professionals, including some within Biden’s administration, think that the [FDA] will authorize MDMA for PTSD and psilocybin for depression within two years. Oregon has lifted prohibitions against medicinal psilocybin, effective in 2023. Some biotech companies are already courting investors with patents for psychedelic-derived medicines,” writes author Nick Keppler of The Daily Beast.

Originally appearing here (Archived)